Key acquisitions since 2022 increased Amgen’s rare disease pipeline and footprint in the market, with the company poised to benefit from the rare disease market’s 10.35% CAGR up to 2037. A growing ...
Syngene Amgen Research and Development Center (SARC) has the following research output in the current window (1 October 2024 - 30 September 2025) of the Nature Index. Click on Count to view a list of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results